Burden of Shigella among children with diarrhea in the Americas: A systematic review and meta-analysis

美洲儿童腹泻中志贺氏菌的负担:系统评价和荟萃分析

阅读:2

Abstract

INTRODUCTION: Shigella is a leading cause of diarrhea worldwide. While the burden of Shigella has been shown to be highest in Africa and Asia, recent studies have also shown considerable burden in the Americas. With several pediatric Shigella vaccines in clinical development, policymakers in the region will eventually consider whether a Shigella vaccine is appropriate for their setting. METHODS: We conducted a systematic review and meta-analyses to summarize the burden (characterized by prevalence, incidence, and attributable fraction estimates) of Shigella diarrhea among children under 72 months in the Americas, excluding the U.S., Canada, and Greenland. We searched published and pre-print articles available in six databases from January 1, 2000 through July 18, 2024. Random effects meta-analyses were conducted for subgroups of interest when relevant data from at least two studies were present. RESULTS: This review included 34 studies conducted across 14 countries in the region. Prevalence was most frequently reported, followed by incidence, then attributable fraction. Across all prevalence studies that used a culture detection method (n = 23), the pooled prevalence of Shigella among diarrhea cases was 3.1% (95% CI: 1.6- 5.8). The pooled prevalence among 7 studies that used PCR/qPCR detection methods was 16.5% (95% CI: 11.1-24.0). Among culture-based results, the pooled prevalence estimate for children <12 months was 1.0% (95% CI: 0.1 - 7.7) compared to 4.6% (95% CI: 1.2 - 15.4) for children ≥12 months. CONCLUSION: Despite varying reporting practices, we found Shigella to be an important contributor to diarrhea in many settings in the Americas with substantial heterogeneity. Limited geographic representation and variable reporting of age group specific estimates were the major gaps in data. Investment in Shigella surveillance in the Americas using a standardized methodology can contribute to accelerating Shigella vaccine development in consideration of regional preferences and optimal age of introduction.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。